DNA Methyltransferase Inhibitors

Epigenetic Targets in Drug Discovery

Volumn 42, Issue , 2010, Pages 161-183

  Sippl, Wolfgang ^a   Jung, Manfred ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

DNA methylation; DNA nucleotide methyltransferases (DNMTs); Epigenetic regulation; Inhibitors

Indexed keywords

EID: 85018193798     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527627073.ch8     Document Type: Chapter

References (113)

1. Kouzarides, T (2007) Chromatin modifications and their function. Cell, 128, 693-705.
2. Bestor, T.H. (2000) The DNA methyltransferases of mammals. Human Molecular Genetics, 9, 2395-2402.
3. Yoo, C.B., Valente, R., Congiatu, C., Gavazza, F., Angel, A., Siddiqui, M.A., Jones, P.A., McGuigan, C. and Marquez, V.E. (2008) Activation of p16 Gene Silenced by DNA Methylation in Cancer Cells by Phosphoramidate Derivatives of 2'-Deoxyzebularine. Journal of Medicinal Chemistry (in press).
4. Allis, C.D., Jenuwein, T. and Reinberg, D. (2007) Overview and concepts, Epigenetics, Cold Spring Harbor Laboratory Press, pp. 23-61.
5. Wolfe, A.P. and Matzke, M.A. (1999) Epigenetics: regulation through repression. Science, 286, 481-486.
6. Lopez-Serra, L. and Esteller, M. (2008) Proteins that bind methylated DNA and human cancer: reading the wrong words. British Journal of Cancer, 98, 1881-1885.
7. Schmutte, C. and Jones, P.A. (1998) Involvement of DNA methylation in human carcinogenesis. Biological Chemistry, 379, 377-388.
8. Morgan, H.D., Dean, W., Coker, H.A., Reik, W. and Petersen-Mahrt, S.K. (2004) Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. The Journal ofBiological Chemistry, 279, 52353-52360.
9. Petersen-Mahrt, S. (2005) DNA deamination in immunity. Immunological Reviews, 203, 80-97.
10. Bird, A. (2002) DNA methylation patterns and epigenetic memory. Genes and Development, 16, 6-21.
11. Ehrlich, M., Gama-Sosa, M.A., Huang, L.H., Midgett, R.M., Kuo, K.C., McCune, R.A. and Gehrke, C. (1982) Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Research, 10, 2709-2721.
12. McCabe, D.C. and Caudill, M.A. (2005) DNA methylation, genomic silencing, and links to nutrition and cancer. Nutrition Reviews, 63, 183-195.
13. Gardiner-Garden, M. and Frommer, M. (1987) CpG islands in vertebrate genomes. Journal of Molecular Biology, 196, 261-282.
14. Takai, D. and Jones, P.A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proceedings of the National Academy of Sciences ofthe United States ofAmerica, 99, 3740-3745.
15. Dunn, B.K. (2003) Hypomethylation: one side of a larger picture. Annals of the New York Academy of Sciences, 983, 28-42.
16. Ooi, S.K. and Bestor, T.H. (2008) The colorful history of active DNA demethylation. Cell, 133, 1145-1148.
17. Kangaspeska, S., Stride, B., Metivier, R., Polycarpou-Schwarz, M., Ibberson, D., Carmouche, R.P., Benes, V., Gannon, F. and Reid, G. (2008) Transient cyclical methylation of promoter DNA. Nature, 452, 112-115.
18. Metivier, R., Gallais, R., Tiffoche, C., Le Peron, C., Jurkowska, R.Z., Carmouche, R.P., Ibberson, D., Barath, P., Demay, F., Reid, G., Benes, V., Jeltsch, A., Gannon, F. and Salbert, G. (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature, 452, 45-50.
19. Okano, M., Xie, S. and Li, E. (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nature Genetics, 19, 219-220.
20. Bestor, T., Laudano, A., Mattaliano, R. and Ingram, V. (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. Journal of Molecular Biology, 203, 971-983.
21. Yoder, J.A. and Bestor, T.H. (1998) A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. Human Molecular Genetics, 7, 279-284.
22. Goll, M.G. and Bestor, T.H. (2005) Eukaryotic cytosine methyltransferases. Annual Review of Biochemistry, 74, 481-514.
23. Goll, M.G., Kirpekar, F., Maggert, K.A., Yoder, J.A., Hsieh, C.L., Zhang, X., Golic, K.G., Jacobsen, S.E. and Bestor, T.H. (2006) Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science, 311, 395-398.
24. Posfai, J., Bhagwat, A.S., Posfai, G. and Roberts, R.J. (1989) Predictive motifs derived from cytosine methyltransferases. Nucleic Acids Research, 17, 2421-2435.
25. Lauster, R., Trautner, T.A. and Noyer-Weidner, M. (1989) Cytosine-specifictype II DNA methyltransferases. A conserved enzyme core with variable targetrecognizing domains. Journal ofMolecular Biology, 206, 305-312.
26. Cheng, X. and Blumenthal, R.M. (2008) Mammalian DNA methyltransferases: a structural perspective. Structure (London, England: 1993), 16, 341-350.
27. Qiu, C., Sawada, K., Zhang, X. and Cheng, X. (2002) The PWWP domain of mammalian DNA methyltransferase Dnmt3b defines a new family of DNA-binding folds. Nature Structural Biology, 9, 217-224.
28. Ooi, S.K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S.P., Allis, C.D., Cheng, X. and Bestor, T.H. (2007) DNMT3L connects unmethylated lysine 4 ofhistone H3 to de novo methylation of DNA. Nature, 448, 714-717.
29. Jia, D., Jurkowska, R.Z., Zhang, X., Jeltsch, A. and Cheng, X. (2007) Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature, 449, 248-251.
30. Siedlecki, P., Boy, R.G., Musch, T., Brueckner, B., Suhai, S., Lyko, F. and Zielenkiewicz, P. (2006) Discovery of two novel, small-molecule inhibitors of DNA methylation. Journal of Medicinal Chemistry, 49, 678-683.
31. Siedlecki, P., Boy, R.G., Comagic, S., Schirrmacher, R., Wiessler, M., Zielenkiewicz, P., Suhai, S. and Lyko, F. (2003) Establishment and functional validation ofa structural homology model for human DNA methyltransferase 1. Biochemical and Biophysical Research Communications, 306, 558-563.
32. Vilkaitis, G., Merkiene, E., Serva, S., Weinhold, E. and Klimasauskas, S. (2001) The mechanism of DNA cytosine-5 methylation. Kinetic and mutational dissection of Hhai methyltransferase. The Journal ofBiological Chemistry, 276, 20924-20934.
33. O'Gara, M., Klimasauskas, S., Roberts, R.J. and Cheng, X. (1996) Enzymatic C5-cytosine methylation of DNA: mechanistic implications of new crystal structures for HhaL methyltransferase-DNA-AdoHcy complexes. Journal of Molecular Biology, 261, 634-645.
34. Klimasauskas, S., Kumar, S., Roberts, R.J. and Cheng, X. (1994) Hhal methyltransferase flips its target base out of the DNA helix. Cell, 76, 357-369.
35. Zhou, L., Cheng, X., Connolly, B.A., Dickman, M.J., Hurd, P.J. and Hornby, D.P. (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. Journal ofMolecular Biology, 321, 591-599.
36. Brannan, C.I. and Bartolomei, M.S. (1999) Mechanisms of genomic imprinting. Current Opinion in Genetics & Development, 9, 164-170.
37. Hansen, R.S. (2003) X inactivation-specific methylation of LINE-1 elements by DNMT3B: implications for the Lyon repeat hypothesis. Human Molecular Genetics, 12, 2559-2567.
38. Watt, F. and Molloy, P.L. (1988) Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes and Development, 2, 1136-1143.
39. Wade, P.A. (2001) Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene, 20, 3166-3173.
40. Lopez-Serra, L., Ballestar, E., Ropero, S., Setien, F., Billard, L.M., Fraga, M.F., Lopez-Nieva, P., Alaminos, M., Guerrero, D., Dante, R. and Esteller, M. (2008) Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene, 27, 3556-3566.
41. Fahrner, J.A., Eguchi, S., Herman, J.G. and Baylin, S.B. (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Research, 62, 7213-7218.
42. Kondo, Y., Shen, L. and Issa, J.P. (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Molecular and Cellular Biology, 23, 206-215.
43. Venturelli, S., Armeanu, S., Pathil, A., Hsieh, C.J., Weiss, T.S., Vonthein, R., Wehrmann, M., Gregor, M., Lauer, U.M. and Bitzer, M. (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer, 109, 2132-2141.
44. Griffiths, E.A. and Gore, S.D. (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in Hematology, 45, 23-30.
45. Walton, T.J., Li, G., Seth, R., McArdle, S.E., Bishop, M.C. and Rees, R.C. (2008) DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate, 68, 210-222.
46. Li, E., Bestor, T.H. and Jaenisch, R. (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 69, 915-926.
47. Ateeq, B., Unterberger, A., Szyf, M. and Rabbani, S.A. (2008) Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia (New York, NY), 10, 266-278.
48. Choi, J.K. and Kim, S.C. (2007) Environmental effects on gene expression phenotype have regional biases in the human genome. Genetics, 175, 1607-1613.
49. Weidman, J.R., Dolinoy, D.C., Murphy, S.K. and Jirtle, R.L. (2007) Cancer susceptibility: Epigenetic manifestation of environmental exposures. Cancer Journal (Sudbury, Mass), 13, 9-16.
50. Jones, P.A. and Baylin, S.B. (2007) The epigenomics of cancer. Cell, 128, 683-692.
51. Kuratomi, G., Iwamoto, K., Bundo, M., Kusumi, I., Kato, N., Iwata, N., Ozaki, N. and Kato, T. (2008) Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Molecular Psychiatry, 13, 429-441.
52. Kaminsky, Z., Petronis, A., Wang, S.C., Levine, B., Ghaffar, O., Floden, D. and Feinstein, A. (2008) Epigenetics of personality traits: An illustrative study of identical twins discordant for risk-taking behavior. Twin Research and Human Genetics, 11, 1-11.
53. Fraga, M.F., Ballestar, E., Paz, M.F., Ropero, S., Setien, F., Ballestart, M.L., Heine-Suner, D., Cigudosa, J.C., Urioste, M., Benitez, J., Boix-Chornet, M., Sanchez-Aguilera, A., Ling, C., Carlsson, E., Poulsen, P., Vaag, A., Stephan, Z., Spector, T.D., Wu, Y.Z., Plass, C. and Esteller, M. (2005) Epigenetic differences arise during the lifetime ofmonozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 102, 10604-10609.
54. Esteller, M. (2006) The necessity of a human epigenome project. Carcinogenesis, 27, 1121-1125.
55. Wang, S.S., Smiraglia, D.J., Wu, Y.Z., Ghosh, S., Rader, J.S., Cho, K.R., Bonfiglio, T.A., Nayar, R., Plass, C. and Sherman, M.E. (2008) Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Research, 68, 2489-2497.
56. Yu, L., Liu, C., Vandeusen, J., Becknell, B., Dai, Z., Wu, Y.Z., Raval, A., Liu, T.H., Ding, W., Mao, C., Liu, S., Smith, L.T., Lee, S., Rassenti, L., Marcucci, G., Byrd, J., Caligiuri, M.A. and Plass, C. (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene inhumanleukemia. Nature Genetics, 37, 265-274.
57. Mulero-Navarro, S. and Esteller, M. (2008) Epigenetic biomarkers for human cancer:The time is now. Critical Reviews in Oncology/Hematology, 68, 1-11.
58. Baylin, S.B. and Herman, J.G. (2000) DNAhypermethylation in tumorigenesis: epigenetics joins genetics. Trends in Genetics, 16, 168-174.
59. Costello, J.F. and Plass, C. (2001) Methylation matters. Journal of Medical Genetics, 38, 285-303.
60. Esteller, M. (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21, 5427-5440.
61. Butcher, D.T. and Rodenhiser, D.I. (2007) Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. European Journal of Cancer (Oxford, England: 1990), 43, 210-219.
62. Lin, R.K., Hsu, H.S., Chang, J.W., Chen, C.Y., Chen, J.T. and Wang, Y.C. (2007) Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer (Amsterdam, Netherlands), 55, 205-213.
63. Liu, S., Shen, T., Huynh, L., Klisovic, M.I., Rush, L.J., Ford, J.L., Yu, J., Becknell, B., Li, Y, Liu, C., Vukosavljevic, T., Whitman, S.P., Chang, K.S., Byrd, J.C., Perrotti, D., Plass, C. and Marcucci, G. (2005) Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Research, 65, 1277-1284.
64. Ostler, K.R., Davis, E.M., Payne, S.L., Gosalia, B.B., Exposito-Cespedes, J., Le Beau, M.M. and Godley, L.A. (2007) Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene, 26, 5553-5563.
65. Costello, J.F. and Plass, C. (2001) Methylation matters. Journal of Medical Genetics, 38, 285-303.
66. Esteller, M. (2008) Epigenetics in cancer. The New England Journal of Medicine, 358, 1148-1159.
67. Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setien, F., Casado, S., Suarez-Gauthier, A., Sanchez-Cespedes, M., Git, A., Spiteri, I., Das, P.P., Caldas, C., Miska, E. and Esteller, M. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Research, 67, 1424-1429.
68. Jones, P.A. and Taylor, S.M. (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20, 85-93.
69. Christman, J.K. (2002) 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 21, 5483-5495.
70. Stresemann, C., Brueckner, B., Musch, T., Stopper, H. and Lyko, F. (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Research, 66, 2794-2800.
71. Byun, H.M., Choi, S.H., Laird, P.W., Trinh, B., Siddiqui, M.A., Marquez, V.E. and Yang, A.S. (2008) 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Letters, 266, 238-248.
72. Plagemann, P.G., Behrens, M. and Abraham, D. (1978) Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Research, 38, 2458-2466.
73. Brueckner, B., Kuck, D. and Lyko, F. (2007) DNA methyltransferase inhibitors for cancer therapy. Cancer Journal (Sudbury, Mass), 13, 17-22.
74. Santi, D.V., Garrett, C.E. and Barr, P.J. (1983) On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell, 33, 9-10.
75. Xiang, S.B., Short, S.A., Wolfenden, R. and Carter, C.W. (1995) Transition-state selectivity for a single hydroxyl group during catalysis by cytidine deaminase. Biochemistry, 34, 4516-4523.
76. Laliberte, J., Marquez, V.E. and Momparler, R.L. (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemotherapy and Pharmacology, 30, 7-11.
77. Lemaire, M., Momparler, L.F., Bernstein, M.L., Marquez, V.E. and Momparler, R.L. (2005) Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Anti-Cancer Drugs, 16, 301-308.
78. Lemaire, M., Momparler, L.F., Raynal, N.J., Bernstein, M.L. and Momparler, R.L. (2009) Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemotherapy and Pharmacology, 63, 411-416.
79. Klecker, R.W., Cysyk, R.L. and Collins, J.M. (2006) Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Bioorganic and Medicinal Chemistry, 14, 62-66.
80. Ben-Kasus, T., Ben-Zvi, Z., Marquez, V.E., Kelley, J.A. and Agbaria, R. (2005) Metabolic activation ofzebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochemical Pharmacology, 70, 121-133.
81. Stresemann, C. and Lyko, F. (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer, 123, 8-13.
82. Brueckner, B., Boy, R.G., Siedlecki, P., Musch, T., Kliem, H.C., Zielenkiewicz, P., Suhai, S., Wiessler, M. and Lyko, F. (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Research, 65, 6305-6311.
83. Arce, C., Segura-Pacheco, B., Perez-Cardenas, E., Taja-Chayeb, L., Candelaria, M. and Duennas-Gonzalez, A. (2006) Hydralazine target: from blood vessels to the epigenome. Journal ofTranslational Medicine, 4, 10.
84. Segura-Pacheco, B., Trejo-Becerril, C., Perez-Cardenas, E., Taja-Chayeb, L., Mariscal, I., Chavez, A., Acuna, C., Salazar, A.M., Lizano, M. and Duenas-Gonzalez, A. (2003) Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clinical Cancer Research, 9, 1596-1603.
85. Villar-Garea, A., Fraga, M.F., Espada, J. and Esteller, M. (2003) Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Research, 63, 4984-4989.
86. Castellano, S., Kuck, D., Sala, M., Novellino, E., Lyko, F. and Sbardella, G. (2008) Constrained analogues ofprocaine as novel small molecule inhibitors of DNA methyltransferase-1. Journal of Medicinal Chemistry, 51, 2321-2325.
87. Hauser, A.-T. and Jung, M. (2008) Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention. Planta Medica (in press).
88. Pina, I.C., Gautschi, J.T., Wang, G.Y., Sanders, M.L., Schmitz, F.J., France, D., Cornell-Kennon, S., Sambucetti, L.C., Remiszewski, S.W., Perez, L.B., Bair, K.W. and Crews, P. (2003) Psammaplins from the sponge Pseudoceratina purpurea: inhibition ofboth histone deacetylase and DNA methyltransferase. The Journal of Organic Chemistry, 68, 3866-3873.
89. Fang, M.Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W. and Yang, C.S. (2003) Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research, 63, 7563-7570.
90. Narayanan, B.A. (2006) Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Current Cancer Drug Targets, 6, 711-727.
91. Lee, W.J. and Zhu, B.T. (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis, 27, 269-277.
92. Fini, L., Selgrad, M., Fogliano, V., Graziani, G., Romano, M., Hotchkiss, E., Daoud, Y.A., De Vol, E.B., Boland, C.R. and Ricciardiello, L. (2007) Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. The Journal of Nutrition, 137, 2622-2628.
93. Fang, M.Z., Chen, D., Sun, Y., Jin, Z., Christman, J.K. and Yang, C.S. (2005) Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clinical Cancer Research, 11, 7033-7041.
94. Lin, R.K., Hsu, C.H. and Wang, Y.C. (2007) Mithramycin A inhibits DNA methyltransferase and metastasis potential oflung cancer cells. Anti-Cancer Drugs, 18, 1157-1164.
95. Davis, A.J., Gelmon, K.A., Siu, L.L., Moore, M.J., Britten, C.D., Mistry, N., Klamut, H., D'Aloisio, S., MacLean, M., Wainman, N., Ayers, D., Firby, P., Besterman, J.M., Reid, G.K. and Eisenhauer, E.A. (2003) Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Investigational New Drugs, 21, 85-97.
96. Winquist, E., Knox, J., Ayoub, J.P., Wood, L., Wainman, N., Reid, G.K., Pearce, L., Shah, A. and Eisenhauer, E. (2006) Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Investigational New Drugs, 24, 159-167.
97. Klisovic, R.B., Stock, W., Cataland, S., Klisovic, M.I., Liu, S., Blum, W., Green, M., Odenike, O., Godley, L., Burgt, J.V., Van Laar, E., Cullen, M., Macleod, A.R., Besterman, J.M., Reid, G.K., Byrd, J.C. and Marcucci, G. (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clinical Cancer Research, 14, 2444-2449.
98. Issa, J.P. (2007) DNA methylation as a therapeutic target in cancer. Clinical Cancer Research, 13, 1634-1637.
99. Melchert, M. and List, A. (2008) Targeted therapies in myelodysplastic syndrome. Seminars in Hematology, 45, 31-38.
100. Sekeres, M.A. (2007) The myelodysplastic syndromes. Expert Opinion on Biological Therapy, 7, 369-377.
101. Laird, P.W., Jackson-Grusby, L., Fazeli, A., Dickinson, S.L., Jung, W.E., Li, E., Weinberg, R.A. and Jaenisch, R. (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81, 197-205.
102. Davis, C.D. and Uthus, E.O. (2002) Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. The Journal of Nutrition, 132, 292-297.
103. Lantry, L.E., Zhang, Z., Crist, K.A., Wang, Y., Kelloff, G.J., Lubet, R.A. and You, M. (1999) 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis, 20, 343-346.
104. McGregor, F., Muntoni, A., Fleming, J., Brown, J., Felix, D.H., MacDonald, D.G., Parkinson, E.K. and Harrison, P.R. (2002) Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Research, 62, 4757-4766.
105. Dixon, R.A. and Ferreira, D. (2002) Genistein. Phytochemistry, 60, 205-211.
106. Dean, N.M., Kanemitsu, M. and Boynton, A.L. (1989) Effects of the tyrosine-kinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and rat liver T51B cells. Biochemical and Biophysical Research Communications, 165, 795-801.
107. Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., Strouboulis, J. and Wolffe, A.P. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. NatureGenetics, 19,187-191.
108. Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N. and Bird, A. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393, 386-389.
109. Zhu, W.G. and Otterson, G.A. (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Current Medicinal Chemistry Anticancer Agents, 3, 187-199.
110. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G. and Baylin, S.B. (1999) Synergy of demethylationand histone deacetylase inhibition in the reexpression ofgenes silenced in cancer. Nature Genetics, 21, 103-107.
111. Kikuchi, T., Itoh, F., Toyota, M., Suzuki, H., Yamamoto, H., Fujita, M., Hosokawa, M. and Imai, K. (2002) Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. International Journal of Cancer, 97, 272-277.
112. Jones, P.A. and Baylin, S.B. (2002) The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics, 3,415-428.
113. Yoo, C.B. and Jones, P.A. (2006) Epigenetictherapyofcancer: past, present and future. Nature Reviews. Drug Discovery, 5, 37-50.